Thoroughbred Financial Services LLC Boosts Stake in Illumina, Inc. (NASDAQ:ILMN)

Thoroughbred Financial Services LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 65.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,662 shares of the life sciences company’s stock after acquiring an additional 1,052 shares during the period. Thoroughbred Financial Services LLC’s holdings in Illumina were worth $355,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of ILMN. WCM Investment Management LLC raised its stake in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after purchasing an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp grew its position in Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock worth $454,617,000 after acquiring an additional 27,618 shares in the last quarter. Geode Capital Management LLC grew its position in Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after acquiring an additional 48,018 shares in the last quarter. Norges Bank bought a new position in Illumina in the fourth quarter valued at $228,714,000. Finally, Pictet Asset Management Holding SA raised its position in Illumina by 245.7% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company’s stock valued at $158,011,000 after purchasing an additional 840,423 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $74.16 on Monday. Illumina, Inc. has a 1 year low of $70.64 and a 1 year high of $156.66. The stock has a market capitalization of $11.75 billion, a P/E ratio of -9.66, a P/E/G ratio of 1.60 and a beta of 1.38. The company’s 50-day moving average is $96.82 and its 200 day moving average is $125.02. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent research reports. Stephens reiterated an “overweight” rating and set a $156.00 price objective on shares of Illumina in a research report on Tuesday, March 11th. Royal Bank of Canada decreased their price target on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 12th. Canaccord Genuity Group reduced their target price on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, March 11th. Piper Sandler lifted their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Finally, Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.